Replies to post #78036 on Avid Bioservices Inc (CDMO)

[jonnyrocket]

CJ do you know the licensing milestones/royalties we may be owed if this is developed or commercially approved? Or did we pay them to take it? Thx

[jessme]

Merck KGaA licensed from Peregrine in 2000.


2-22-07: TNT-based European Cancer Trial initiated by 'Licensee' Clearly, it's Merck-KGaA's 'SELECTIKINE'

4-2011/AACR

7 years from licensing to initiation of trial. 4 more years for AACR presentation.

I'm getting that fuzzy FEEL GOOD from reposts again.

Didn't we give up any milestone payments so we could use their lab facilities? I haven't noticed any payments from them in our filings

Maybe someone can tell me why our outstanding licensing staff had to go through Stason, who had no facilities, to license Cotara and Stason managed to license a deal with Lonza a well established company whose shares are currently about $53? mary sure was running.
http://www.lonza.com/about-lonza/company-profile/company-history.aspx

[freethemice]

CJ, just to be clear, it is the human monoclonal antibody NHS76 that is the piece of the immunocytokine which
has been licensed to Merck. EMD Serono has made NHS-IL2 and NHS-IL12 by conjugating either cytokine
IL-2 or IL-12 to NHS76. NHS76 is the target seeking part of the immunocytokine and IL-2 or IL-12 is delivered
to the site of the tumor to stimulate an immune response. Other immunocytokines have been developed using a
different antibody (different target) conjugated to either IL-2, IL-12, IFN-gamma, or some other cytokine.

[entdoc]

CJ&FTM..while the west coast slept. Amazing stuff. Thanks foryour efforts. I've posted here several times that I can't understand why PPHM had not pushed forward with a fully human Cotara instead of the clunky chimeric MAB being used, and you found that PPHM has had it since at least 2000, and licensed it to MerckeAG. Mind-boggling. So the paper at AACR deals fusing anti-neoplastic IL-12 to a tumor-binding antibody, NHS-IL12, the fully humanized Cotara-like MAB developed by PPHM, an antibody which also targets necrotic portions of tumors because of its high affinity for single- and double-stranded DNA, which are often exposed as tumors outgrow their blood supply. "NHS-IL12 may therefore be useful against a wide range of solid tumors, and mouse models can be used to study its mechanisms of action." Love it. Thanks again.